First-time presentation examining bone outcomes in early postmenopausal womenJERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX),...
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, October...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the...
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experienceVANCOUVER, British Columbia and BOSTON, Oct....
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to...
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7%...
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025...
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International ConferenceAddition of TUS to...
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously...
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct....
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs...
Unveiling AI Clothing Sorting System and New Equipment for Depression Treatment TAIPEI, Oct. 16, 2025 /PRNewswire/ -- The Department of...
AMSTERDAM, Oct. 16, 2025 /PRNewswire/ -- Critical Path Institute® (C-Path) today announced the official launch of the Critical Path Disease...
COLD SPRING HARBOR, N.Y., Oct. 15, 2025 /PRNewswire/ -- The Lustgarten Foundation, the world's largest private funder of pancreatic cancer...
In this free webinar, gain insight into how ICON Strategic Solutions (ISS) delivers Functional Service Provider (FSP) services that outperform...